10-Q: Amgen Q2 2025: Strong Revenue Growth Amidst Pricing Headwinds

Amgen reports significant revenue and earnings growth in Q2 2025, driven by strong product volumes, while navigating increasing pricing pressures and ongoing legal challenges.

Summary

• Total revenues increased by 9% to $9,179 million for the three months ended June 30, 2025, and by 9% to $17,328 million for the six months ended June 30, 2025.
• Net income surged by 92% to $1,432 million for Q2 2025 and by over 100% to $3,162 million for the first half of 2025.
• Diluted EPS rose by 92% to $2.65 for Q2 2025 and by over 100% to $5.84 for the first half of 2025.
• Product sales volume grew by 13% in Q2 2025 and 14% in H1 2025, partially offset by net selling price declines of 3% and 4% respectively.
• Key growth drivers include Repatha (+31% Q2), EVENITY (+32% Q2), BLINCYTO (+45% Q2), TEZSPIRE (+46% Q2), and KRYSTEXXA (+19% Q2).
• ENBREL sales decreased by 34% in Q2 2025 due to unfavorable sales deductions and lower net selling price from increased 340B Program mix and Medicare Part D redesign.
• Otezla sales increased by 14% in Q2 2025, but an $800 million impairment charge was recorded in Q1 2025 due to its selection for Medicare price setting starting January 1, 2027.
• The company repurchased $832 million in principal amount of debt for $602 million in H1 2025, resulting in a $228 million gain on extinguishment.
• A quarterly cash dividend of $2.38 per share was declared for Q2 2025 and Q3 2025, representing a 6% increase over 2024 quarterly dividends.

Sentiment

Score: 6

Explanation: While Amgen demonstrated strong revenue and earnings growth driven by volume and promising pipeline advancements, significant headwinds from U.S. drug pricing policies (IRA, MFN EO, PDABs), ongoing major tax and antitrust litigation with substantial potential liabilities, and impending biosimilar competition for key products (Prolia, XGEVA) introduce considerable uncertainty and financial pressure. The positive clinical updates and debt management are strong, but the external regulatory and competitive environment presents notable challenges.

Positives

• Strong revenue growth of 9% for both the quarter and six-month period, driven by robust product volume increases (13% in Q2, 14% in H1).
• Significant increase in net income and diluted EPS (92% in Q2, over 100% in H1), indicating improved profitability.
• Key product growth: Repatha (+31% Q2), EVENITY (+32% Q2), BLINCYTO (+45% Q2), TEZSPIRE (+46% Q2), and KRYSTEXXA (+19% Q2) demonstrate strong market demand.
• Positive clinical trial results for MariTide (weight loss up to 20%, improved cardiometabolic parameters) and IMDELLTRA/IMDYLLTRA (40% reduction in risk of death in SCLC, improved PFS).
• Bemarituzumab Phase 3 trial met primary endpoint of overall survival in gastric cancer, showing statistically significant and clinically meaningful improvement.
• TEPEZZA received marketing authorization approval in the European Union for thyroid eye disease, expanding its market reach.
• Effective debt management, including opportunistic repurchases resulting in a $228 million gain in H1 2025, and a decrease in total debt outstanding.
• Commitment to shareholder returns through increased quarterly cash dividends ($2.38 per share, 6% increase over 2024) and a substantial remaining stock repurchase authorization of $6.8 billion.

Negatives

• Declines in net selling price (3% in Q2, 4% in H1) partially offset volume growth, indicating ongoing pricing pressures.
• Significant sales decline for ENBREL (-34% Q2, -25% H1) due to increased 340B Program mix, higher commercial discounts, and U.S. Medicare Part D redesign.
• Otezla incurred an $800 million intangible asset impairment charge in Q1 2025 due to its selection for Medicare price setting under the IRA, effective January 1, 2027.
• Prolia and XGEVA sales decreased (-4% and -5% in Q2 respectively), with expected sales erosion in the second half of 2025 due to biosimilar competition following patent expiry in the U.S. (Feb 2025) and Europe (Nov 2025).
• KYPROLIS sales decreased by 7% in H1 2025 due to lower volume from increased competition.
• Cash and cash equivalents decreased from $11,973 million at December 31, 2024, to $8,028 million at June 30, 2025.
• Net cash used in investing activities increased significantly to $836 million in H1 2025 from $434 million in H1 2024, primarily due to higher capital expenditures.

Risks

• Sales are highly dependent on coverage and reimbursement from government and commercial third-party payers, with ongoing and increasing pricing and reimbursement pressures.
• The Inflation Reduction Act (IRA) will negatively impact profitability, with ENBREL subject to Medicare price setting from January 1, 2026, and Otezla from January 1, 2027.
• The One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, includes provisions effective 2026 and beyond that may adversely affect coverage and reimbursement.
• The Most-Favored-Nations (MFN) Executive Order and July MFN Letter aim to use international price benchmarks for U.S. pricing, potentially leading to lower U.S. drug prices and adverse business impacts.
• State-level actions, including Prescription Drug Affordability Boards (PDABs) and drug importation programs, could further limit pricing and access; Colorado's PDAB deemed ENBREL unaffordable.
• Inappropriate expanded utilization of the 340B Program continues to negatively impact product sales.
• Consolidation among commercial payers (insurers, PBMs) increases their negotiating leverage, leading to greater price discounts, rebates, and restrictions on product access.
• Significant tax liabilities are possible from an ongoing IRS dispute for 2010-2012 ($3.6 billion plus interest) and 2013-2015 ($5.1 billion plus interest and $2.0 billion penalties), with a decision expected no earlier than H2 2026.
• Enactment of the OECD global minimum tax agreement (15% minimum tax rate) in various countries, including Singapore (effective Jan 1, 2025), could increase tax liabilities.
• International business operations face risks from geopolitical instability, tariffs (e.g., China's retaliatory tariffs, potential Section 232 pharmaceutical tariff up to 200%), and evolving data privacy regulations.
• Manufacturing difficulties, disruptions, or delays due to capacity issues, contamination, natural disasters, labor shortages, regulatory non-compliance, or supply chain issues could limit product supply and sales.
• Increased costs and potential delays in manufacturing capacity expansion (e.g., Ohio and North Carolina facilities) due to tariffs on imported equipment and construction materials.
• Exposure to market fluctuations and potential impairment charges on the significant investment portfolio, including equity investments, due to interest rate fluctuations, inflation, and credit rating downgrades.
• Cash and cash equivalents held in major financial institutions exceed insured limits, posing a risk if these institutions fail.

Future Outlook

The company expects continued volume growth from certain brands for the remainder of 2025, partially offset by net selling price declines. Spending on Later-Stage Clinical Programs is expected to continue to grow as the pipeline advances. A decision from the U.S. Tax Court regarding the IRS dispute for 2010-2015 is expected no earlier than the second half of 2026. The IRS audit for 2016-2018 is ongoing, and the audit for 2019-2022 is expected to begin in 2025 or early 2026. The company anticipates that existing funds, cash from operations, and access to financing will be adequate to meet future liquidity needs, including investments in innovation, capital expenditures (estimated $2.3 billion for full year 2025), debt reduction, and shareholder returns.

Management Comments

• Robert A. Bradway, Chairman of the Board, Chief Executive Officer and President, and Peter H. Griffith, Executive Vice President and Chief Financial Officer, certified that the quarterly report fairly presents the financial condition, results of operations, and cash flows, and that disclosure controls and internal control over financial reporting are effective.
• Management believes the IRS positions set forth in the 2010-2012 and 2013-2015 Notices are without merit and is contesting them through the judicial process.
• Management believes its accrual for income tax liabilities is appropriate based on past experience, interpretations of tax law, and judgments about potential actions by tax authorities.
• Management believes that the jury's decision and amounts awarded in the Regeneron antitrust action are inconsistent with the law and evidence at trial, and has determined it is not probable to incur a loss from this litigation.

Industry Context

The biotechnology and pharmaceutical industry continues to face significant cost containment measures and pricing pressures from governments and private payers globally, exacerbated by macroeconomic conditions like inflation and geopolitical tensions. The U.S. Inflation Reduction Act (IRA) and state-level Prescription Drug Affordability Boards (PDABs) are directly impacting drug pricing and reimbursement, particularly for established products like ENBREL and Otezla. Consolidation among PBMs and insurers is increasing their negotiating leverage. Despite these headwinds, innovation remains a key driver, with companies like Amgen investing heavily in R&D and advancing late-stage clinical programs, such as GLP-1 agonists (MariTide) and oncology treatments (IMDELLTRA, Bemarituzumab), which are areas of high unmet medical need and significant market potential. The industry is also grappling with complex international tax frameworks and trade policies, including tariffs, which can affect manufacturing costs and supply chains.

Comparison to Industry Standards

• Amgen's reported average weight loss of up to approximately 20% with MariTide in obesity without type 2 diabetes, and up to 17% in obesity with type 2 diabetes, positions it competitively against other GLP-1 agonists like Novo Nordisk's Wegovy (semaglutide) and Eli Lilly's Zepbound (tirzepatide), which have shown weight loss in the range of 15-22.5% in clinical trials. The indication that weight loss had not plateaued by 52 weeks suggests potential for further differentiation.
• IMDELLTRA/IMDYLLTRA's 40% reduction in the risk of death and median overall survival of 13.6 months in small cell lung cancer (SCLC) compared to 8.3 months for standard-of-care chemotherapy is a significant improvement in a difficult-to-treat cancer, potentially offering a new standard given the limited advancements in SCLC treatment compared to other lung cancer types.
• The approval of TEPEZZA in the EU for moderate to severe thyroid eye disease expands its market beyond the U.S., where it has been a significant product for Horizon Therapeutics (now Amgen). This aligns with a trend of seeking broader international market access for specialized therapies.
• The $800 million impairment charge on Otezla due to Medicare price setting under the IRA highlights the significant financial impact of U.S. drug pricing legislation, a challenge faced by many pharmaceutical companies with high-revenue products selected for negotiation, similar to how other companies are assessing the impact on their top-selling drugs.
• The ongoing patent litigation, particularly for biosimilars of Prolia/XGEVA and Repatha, is a common industry challenge as companies defend their intellectual property against generic and biosimilar entrants. The settlement allowing Accord to launch denosumab biosimilars by October 1, 2025, is a typical outcome in such disputes, balancing patent protection with market entry.

Legal Proceedings

• Repatha Patent Litigation (Germany): Regional Court of Munich considering Sanofi-Aventis and Regeneron's damages request, hearing rescheduled to December 2025.
• Repatha Patent Litigation (Unified Patent Court of the European Union): Dusseldorf Local Division ruled EP712 Patent valid but not infringed by Amgen; both Amgen and Sanofi/Regeneron filed appeals. Sanofi filed motion to stay lawsuit on EP857 Patent, opposed by Amgen. Oral argument on Amgen's appeal to set aside revocation of EP797 patent rescheduled to August 12, 2025.
• Repatha Patent Litigation (European Patent Office): EPO Board of Appeal accelerated Amgen's appeal on Regeneron's EP712 Patent validity (oral argument March 26, 2026). Amgen filed opposition against Regeneron's EP857 Patent, proceedings accelerated.
• Repatha Patent Litigation (Japan): Amgen filed appeal with Supreme Court of Japan for monetary compensation for past patent infringement against Sanofi K.K.
• Prolia/XGEVA Biologics Price Competition and Innovation Act (BPCIA) Litigation: Confidential settlement with Accord allows launch of denosumab biosimilars as early as October 1, 2025. Lawsuits filed against Shanghai Henlius Biotech Inc./Organon LLC and Hikma Pharmaceuticals USA Inc./Gedeon Richter Plc. on June 25, 2025, and Biocon Biologics on June 30, 2025, alleging infringement of multiple patents for denosumab biosimilars, seeking injunctions and monetary remedies. All consolidated into In Re: Denosumab Patent Litigation multi-district litigation.
• PAVBLU (aflibercept-ayyh) Patent Litigation: Regeneron filed lawsuit on June 17, 2025, alleging infringement of a formulation patent, seeking damages and injunction. Case transferred to U.S. District Court for the Northern District of West Virginia for coordinated pretrial proceedings.
• Antitrust Class Action (Regeneron Pharmaceuticals, Inc.): Jury returned a verdict on May 15, 2025, finding for Regeneron on federal and state antitrust law and tortious interference claims, awarding $135.6 million in compensatory damages (subject to trebling) or $406.8 million (compensatory plus punitive) on tortious interference. Amgen believes the decision is inconsistent with law and evidence and filed post-trial motions. Amgen has not recorded a liability, believing it is not probable to incur a loss.
• Antitrust Action (Sandoz Inc.): Amgen filed a motion to dismiss the complaint on June 20, 2025.
• U.S. Tax Litigation and Related Matters (Amgen Inc. & Subsidiaries v. Commissioner of Internal Revenue): Trial for 2010-2012 and 2013-2015 tax years concluded January 17, 2025. Post-trial briefs filed June 13, 2025, oral argument held July 16, 2025, with reply briefs due October 2025. A decision is expected no earlier than the second half of 2026. The IRS seeks approximately $3.6 billion (2010-2012) and $5.1 billion (2013-2015) in additional federal tax, plus interest, and $2.0 billion in penalties for 2013-2015. Amgen firmly believes the IRS positions are without merit. Examinations for 2016-2018 are ongoing, and 2019-2022 audit is expected to begin in 2025 or early 2026.
• Securities Class Action Litigation (Roofers Local No. 149 Pension Fund): Deadline to file summary judgment motions rescheduled to October 19, 2026.
• Shareholder Derivative Actions: Multiple derivative actions consolidated in Delaware and New York courts, alleging claims purportedly on behalf of Amgen against nominal defendant Amgen and certain officers/directors. Delaware case stayed pending final judgment in federal securities class action.
• ChemoCentryx, Inc. Securities Matters: Lead plaintiff filed motion for partial summary judgment, defendants filed opposition and motion for summary judgment. Hearing set for August 7, 2025. Trial rescheduled to February 23, 2026. Federal case stayed pending class action resolution.

Stakeholder Impact

• Shareholders: Positive impact from increased dividends and ongoing stock repurchase program. Potential negative impact from significant legal and tax liabilities, and pricing pressures on key products.
• Patients/Customers: Potential for reduced access or increased out-of-pocket costs due to government and commercial payer cost-containment measures and pricing policies. Positive impact from new product approvals and pipeline advancements (MariTide, IMDELLTRA, Bemarituzumab, TEPEZZA EU approval).
• Employees: Stock-based compensation programs are in place. No specific negative or positive impacts on employment or compensation trends were detailed.
• Suppliers/Creditors: Debt repayments and opportunistic repurchases benefit creditors. Manufacturing and supply chain risks, including those from tariffs and geopolitical conflicts, could impact suppliers.
• Regulatory Authorities: Ongoing engagement with FDA, EMA, CMS, and tax authorities due to product approvals, pricing regulations, and tax disputes.

Next Steps

• Volume growth from certain brands is expected for the remainder of 2025.
• Net selling price declines are expected to partially offset volume growth for the remainder of 2025.
• Continued growth in spending on Later-Stage Clinical Programs as the pipeline advances.
• Post-trial reply briefs for the IRS tax dispute are scheduled to be filed in October 2025.
• A decision from the U.S. Tax Court on the IRS dispute is expected no earlier than the second half of 2026.
• The IRS audit of 2019-2022 is expected to begin in 2025 or early 2026.
• The hearing for post-trial motions in the Regeneron Pharmaceuticals, Inc. Antitrust Action is set for August 27, 2025.
• The trial for ChemoCentryx, Inc. Securities Matters is rescheduled to begin February 23, 2026.
• Accord is allowed to launch its denosumab biosimilar products in the United States as early as October 1, 2025.
• Prolia and XGEVA patents will expire in select European countries in November 2025, leading to expected sales erosion.
• Medicare price setting for ENBREL will become applicable beginning January 1, 2026.
• Medicare price setting for Otezla will become applicable beginning January 1, 2027.
• The Colorado PDAB's Upper Payment Limit (UPL) for ENBREL could be effective as soon as Q1 2026.
• Washington state's PDAB may not establish a UPL for any prescription drug before January 1, 2027.
• Full year 2025 investments in capital projects are estimated to be approximately $2.3 billion.

Key Dates

Recommendation

Amgen's Q2 2025 results show strong top-line growth driven by volume and impressive pipeline advancements, particularly with MariTide and IMDELLTRA, which could be significant future revenue drivers. The company is also actively managing its debt and returning capital to shareholders through increased dividends. However, these positives are significantly counterbalanced by substantial headwinds. The impact of the IRA on key products like ENBREL and Otezla, coupled with impending biosimilar competition for Prolia and XGEVA, signals sustained pressure on net selling prices and future revenue erosion for established franchises. Furthermore, the ongoing, high-stakes IRS tax dispute and the recent adverse jury verdict in the Regeneron antitrust case represent material contingent liabilities that introduce considerable uncertainty. While Amgen is contesting these, the potential financial impact is substantial. Given the mix of strong operational performance and pipeline progress against significant regulatory, competitive, and legal challenges, a 'hold' recommendation is appropriate. Investors should monitor the outcomes of the legal and tax disputes, the pace of biosimilar erosion, and the commercialization success of pipeline assets.

Keywords

Biotechnology, Pharmaceuticals, SEC Filing, 10-Q, Financial Results, Product Sales, Drug Development, Clinical Trials, Regulatory Approval, Pricing Pressure, Medicare, IRA, Biosimilars, Patent Litigation, Tax Dispute, Amgen